Arrow
Arrow
Slider

Laboratory of Tumor Biology

Laboratory of Tumor Biology (LTB) was founded in 2006 as a joint research facility of Department of Experimental Biology (Faculty of Science, Masaryk University) and Clinic of Children Oncology (Faculty of Medicine, Masaryk University and University Hospital Brno).

Research activities of LTB follow up on those of Laboratory of Tissue Cultures (Department of Biology, Faculty of Medicine, MUNI), whose primary field of study included induced differentiation and the role of cytoskeleton in the process of apoptosis in the years of 1996-2005 (prof. Veselská, assoc. prof. J. Neradil).

Since 2015, our team has been collaborating with the International Clinical Research Center of Saint Anne’s University Hospital (FNUSA-ICRC), in the LOTR research group (Laboratory Oncology Translational Research).

Laboratory focus

LTB facility is focused on solid tumor research, predominantly those of children’s age. All of our research projects are tightly connected to clinical application and our primary goal is to characterize biological attributes of tumors that could specify diagnosis and prognosis, thereby guiding the selection of the best suited therapy for each individual patient. Such attributes contribute to the elucidation of exact cellular and molecular mechanisms in the process of oncogenesis.

Our current research topics include:

  • Receptor Tyrosine-kinase and MAP-kinase activity in pediatric tumors prone to relapse
  • Mechanism of Cancer Stem Cells tumorigenesis in sarcomas
  • Prognostic and predictive biomarkers in neurogenic solid tumors
  • Combined anti-tumor therapy strategies

We routinely utilise primary, as well as reference cell lines of cancer origin, xenograft cancer models and archived samples of patient tumor tissue (in co-operation with several pathology facilities).

Co-operation

Our international research partners include:

  • Michael Hogarty (Children’s Hospital of Philadelphia, PA, USA)
  • Lucília Saraiva (University of Porto, Portugal)
  • Patric Jan Jansson (University of Sydney, Australia)
  • Prof. Igor Adameyko (Medical University of Vienna, Austria & Karolinska Institutet, Sweden)

Furthermore, we collaborate with the following institutions:

  • Regional center for applied and molecular oncology (RECAMO), Masaryk Institute of Oncology, Brno – Assoc. prof. Dalibor Valík, Dr. Petr Müller
  • 1st Pathological-anatomical institute, St. Anne’s University Hospital, Brno – Dr. Iva Zambo, Prof. Markéta Hermanová
  • 1st Orthopedic Clinic, St. Anne’s University Hospital – Dr. Michal Mahdal

Financial support

Our current research projects are funded by the following institutions:

  • Another paper in IJMS

    Another paper in IJMS

    Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma. Int. J. Mol. Sci. 2022, 23(1): 376. Peter Macsek, Jan Skoda,Maria Krchniakova, Jakub Neradil, Renata Veselska https://www.mdpi.com/1422-0067/23/1/376/htm Více »
  • New review in Antioxidants

    New review in Antioxidants

    Tumour Microenvironment Stress Promotes the Development of Drug Resistance. Antioxidants 2021, 10(11): 1801. Nicole A. Seebacher, Maria Krchniakova, Alexandra E. Stacy, Jan Skoda, Patric J. Jansson. https://www.mdpi.com/2076-3921/10/11/1801 Více »
  • New paper in Cancer Letters (IF 8.679)!

    New paper in Cancer Letters (IF 8.679)!

    Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. Cancer Letters 2022, 525: 131-145. Lucie Curylova, Helena Ramos, Lucília Saraiva, Jan Skoda. https://doi.org/10.1016/j.canlet.2021.10.037 Více »
  • New paper in Pediatric Blood & Cancer!

    Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. Pediatr Blood Cancer 2021, e29401. Andrew D. Woods, Noah E. Berlow, Michael V. Ortiz, Filemon Dela Cruz, Armaan Siddiquee, Diego F. Coutinho, … Více »
  • New paper in Cancers!

    New paper in Cancers!

    Novel New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling. Cancers 2021, 12:3781. Michal Mahdal, … Více »
Zobrazit starší aktuality